Kitchens, John W.Kassem, NawalWood, WilliamStone, Thomas W.Isernhagen, RickWood, EdwardHancock, Brad A.Radovich, MilanWaymire, JoshLi, LangSchneider, Bryan P.2025-04-302025-04-302013Kitchens JW, Kassem N, Wood W, et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol. 2013;7:1987-1993. doi:10.2147/OPTH.S39635https://hdl.handle.net/1805/47545Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.en-USAttribution-NonCommercial 4.0 InternationalAge related macular degenerationBevacizumabComplement factor H (CFH)RanibizumabSingle nucleotide polymorphismsVascular endothelial growth factorArticle